We are live on ! Find out more
KPTI icon

Karyopharm Therapeutics
KPTI

80 hedge funds and large institutions have $345M invested in Karyopharm Therapeutics in 2017 Q1 according to their latest regulatory filings, with 13 funds opening new positions, 31 increasing their positions, 22 reducing their positions, and 13 closing their positions.

New
Increased
Maintained
Reduced
Closed

158% more call options, than puts

Call options by funds: $2.04M | Put options by funds: $790K

44% more capital invested

Capital invested by funds: $239M → $345M (+$105M)

41% more repeat investments, than reductions

Existing positions increased: 31 | Existing positions reduced: 22

0.15% more ownership

Funds ownership: 4.12% → 4.27% (+0.15%)

0% more first-time investments, than exits

New positions opened: 13 | Existing positions closed: 13

7% less funds holding

Funds holding: 86 → 80 (-6)

Holders
80
Holders Change
-6
Holders Change %
-6.98%
% of All Funds
1.99%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
13
Increased
31
Reduced
22
Closed
13
Calls
$2.04M
Puts
$790K
Net Calls
+$1.25M
Net Calls Change
+$280K

Top Buyers

Rank Fund Capital Flow
1
BlackRock
BlackRock
New York
+$26.8M
2
TA
Teachers Advisors
New York
+$4.06M
3
SSA
Schonfeld Strategic Advisors
New York
+$3.64M
4
IHM
Iguana Healthcare Management
New York
+$2.94M
5
EI
EAM Investors
California
+$2.89M

Top Sellers

Rank Fund Capital Flow
1
Millennium Management
Millennium Management
New York
-$4.84M
2
Fidelity Investments
Fidelity Investments
Massachusetts
-$4.34M
3
CS
Candriam SCA
Luxembourg
-$2.33M
4
TC
TFS Capital
Pennsylvania
-$987K
5
Franklin Resources
Franklin Resources
California
-$887K
Name Holding Trade Value Shares
Change 		Change in
Stake
MAM
76
Meeder Asset Management
Ohio
$5K -$10.9K -68 -75%
IUHSA
77
Itau Unibanco Holding S.A.
Brazil
$4K +$3.05K +19 New
TDC
78
Thompson Davis & Co
Virginia
$3K +$2.73K +17 New
IA
79
IFP Advisors
Florida
$2K – – –
KF
80
Krilogy Financial
Missouri
$2K – – –
TC
81
TFS Capital
Pennsylvania
– -$987K -7,003 Closed
EIM
82
Essex Investment Management
Massachusetts
– -$524K -3,720 Closed
PCM
83
Piermont Capital Management
Missouri
– -$480K -3,405 Closed
HCM
84
Highbridge Capital Management
New York
– -$376K -2,664 Closed
PCM
85
Prelude Capital Management
New York
– -$303K -2,146 Closed
TI
86
Trexquant Investment
Connecticut
– -$273K -1,934 Closed
Squarepoint
87
Squarepoint
New York
– -$161K -1,140 Closed
EWM
88
Endurance Wealth Management
Rhode Island
– -$171K -1,067 Closed
SG Americas Securities
89
SG Americas Securities
New York
– -$144K -1,023 Closed
Tudor Investment Corp
90
Tudor Investment Corp
Connecticut
– -$109K -775 Closed
TRCT
91
Tower Research Capital (TRC)
New York
– -$23K -165 Closed
CLOS
92
Compagnie Lombard Odier SCmA
Switzerland
– -$17K -120 Closed
Envestnet Asset Management
93
Envestnet Asset Management
Illinois
– -$1K -6 Closed
1 2 3
4

KPTI Hedge Fund Activity: Q1 2017 in Review

80 of the 4,018 institutional investors tracked by Wall St. Rank reported a position in Karyopharm Therapeutics (KPTI) for Q1 2017, worth a combined $345M — up 44% from $239M a quarter earlier.

Fund positioning in KPTI was balanced in Q1 2017: 13 funds opened new positions, 13 closed out, 31 added to existing stakes and 22 trimmed.

The largest buyer was BlackRock, adding an estimated $26.8M. The largest seller was Millennium Management, cutting an estimated $4.84M.

  • 80 institutional investors held Karyopharm Therapeutics (KPTI) as of Q1 2017, down from 86 in Q4 2016.
  • Funds reported $345M of Karyopharm Therapeutics stock for Q1 2017, up 44% quarter-over-quarter.
  • 13 funds opened new Karyopharm Therapeutics positions in Q1 2017 and 13 closed out, a net change of 0 holders.
  • The largest Karyopharm Therapeutics buyer in Q1 2017 was BlackRock, an estimated $26.8M added.
  • The largest Karyopharm Therapeutics seller in Q1 2017 was Millennium Management, an estimated $4.84M sold.

Based on aggregated 13F filings for Q1 2017.